You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
The Israeli online genealogy company recently expanded its ancestry genetic testing offering to include health information.
The Australian startup, recently out of stealth mode, is reviving the concept of sequencing analysis by mutagenesis for NGS library preparation.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The company is seeing increasing interest in its GeoMx platform with numerous studies from early users presented last month at AACR.
The upgrades include a method to connect Panther systems to create a higher-throughput system that can be configured to different footprints.
Though the test is already commercially available, the firm met with the FDA last year to discuss plans for a randomized controlled trial to support regulatory approval.
The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.
The new IQvia E360 Genomics build includes a "privacy-preserving" database system and will soon have analytic tools to support genotype-phenotype research.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.